Microbot Medical (MBOT)
(Delayed Data from NSDQ)
$1.00 USD
+0.01 (1.01%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $1.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
MBOT 1.00 +0.01(1.01%)
Will MBOT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MBOT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MBOT
Microbot Medical (MBOT) Inks Deal to Test Autonomous Robotics
Microbot Medical (MBOT) Progresses in Its Human Clinical Trial
MBOT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Microbot Medical (MBOT) Inks Agreement to Begin LIBERTY Trial
Microbot (MBOT) Inks a New Agreement to Begin Trial on LIBERTY
Microbot Medical (MBOT) Files IDE to Start Human Clinical Study
Other News for MBOT
MBOT Stock Earnings: Microbot Medical Meets EPS for Q2 2024
Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization
Microbot Medical Nears Global Compliance, Eyes Future Goals
Microbot receives certification to support future regulatory submissions
Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY? Endovascular Robotic Surgical System